Cardiopulmonary Exercise Testing Market Research Report - Forecast till 2027

Cardiopulmonary Exercise Testing Market: Information by Product (Cardiopulmonary Exercise Testing (CPET) Systems, Single-Photon Emission Computed Tomography (SPECT), Echocardiogram, Pulse Oximeters, Stress Blood Pressure Monitors and others), by End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East Africa) - Forecast till 2027

ID: MRFR/HC/5163-CR | July 2019 | Region: Global | 157 pages         

Cardiopulmonary Exercise Testing Market

Cardiopulmonary Exercise Testing Market will grow at CAGR of 4.5% to hit $4.98 Billion by 2030

Segmentation

By Product Cardiopulmonary Exercise Testing (CPET) Systems Single-Photon Emission Computed Tomography (SPECT) Echocardiogram Pulse Oximeters Stress Blood Pressure Monitors
By End User Hospitals & Clinics Diagnostic Centers Ambulatory Surgical Centers

Key Players

  • Cardinal Health
  • COSMED SRL
  • GE Healthcare
  • Hill-Rom Holdings Inc.
  • Koninklijke Philips NV
  • MGC Diagnostics Corporation
  • Nihon Kohden Corporation
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc.

Drivers

  • Rising prevalence of cardiovascular
  • Respiratory system-related diseases
Speak to Analyst Request a Free Sample

Cardiopulmonary Exercise Testing Market Analysis


The value of the Cardiopulmonary exercise testing market is growing day by day. This testing helps in detecting disorders related to the heart and lungs which are the major internal organs. The Global cardiopulmonary exercise testing market was valued at USD 3 billion in 2020.


There has been a worldwide spike in the number of patients suffering from cardiopulmonary disorders. Therefore to check and maintain the health conditions of such patients cardiopulmonary exercise testing systems play an important role. Therefore, this growing market is estimated to reach a value of USD 3153.20 Mn by the end of the current forecast period in 2023.


Mostly related to lifestyle change and rising pollution levels, heart, and lung-related disorders have become a serious issue. Many healthcare research labs are spending a lot of resources to develop user-friendly and accurate testing devices. The compound annual growth rate CAGR value for this market is estimated to be around 5.80 % during 2017 – 2023.


Covid 19 Analysis of Cardiopulmonary Exercise Testing Market


Covid brought a huge change in the market valuation of the cardiopulmonary testing market. While due to a sudden spike in the number of covid cases, the industry was unable to meet the rising demand. Disruptions in the supply chain owing to restrictions were the major growth hindering factor.


The demand shot up for both costly large testing machines and small pocket testing devices too. Small handy devices to monitor oxygen saturation, blood pressure, temperature such as oximeters were in higher demand. The cardiopulmonary exercise testing market is expected to surpass the pre covid growth rate quickly. 


Cardiopulmonary Exercise Testing Market Dynamics


Drivers


Cardiopulmonary problems are being more common among people of different regions owing to lifestyle changes. Moreover, these problems are more common in developed countries, thus the demand is significant in such countries. To cope up with rising cases, healthcare institutes are swiftly adopting cardiopulmonary exercise testing ( CPET ).


Another fueling factor for the rise is the technological advancements in the field of medicine. Cardiopulmonary exercise testing can detect the disorders in their early stage and pave the way for correct treatment. It can direct the medicinal practitioner towards a specific problem rather than going for a general treatment. Therefore, this exercise testing greatly enhances the success rate of a treatment.  


The rise in disposable income of people in developing countries and also in patients count will be driving the growth. Moreover, a rise in the agile population who are more prone to such disorders in different countries will too generate the demand.


Restraints 


The major hindrance to the growth of the Cardiopulmonary exercise testing market is the cost factor. The high cost of exercising systems and analyzing devices is still much higher for small hospitals and diagnostic centers. 


On the other hand, the shortage of skilled workers and analysts for operating the system also restricts the growth of the market. Lack of general awareness among people about such testings and negligence towards medical treatment are negative factors too.


Technology Analysis


Cardiopulmonary exercise testing evaluates the performance and health of the heart and lungs for patients suffering from cardiopulmonary disorders. Cardiopulmonary disorders are problems related to the heart and lungs. This tool tests the performance of both the organs at rest and at during exercise to show the deviation from normal behavior.  The patient is required to run a stationary bicycle ergometer with superficial electrodes in his chest to measure electrical pulses in the heart. Moreover, his gas exchange capacity is monitored using special tube masks.


Cardiopulmonary exercise testings give insightful data to the doctors and can also predict future conditions. Such testing also incorporates a large number of general testings such as pulse rate, electrocardiography, etc. Therefore it will help in greatly reducing the general diagnosis and monitoring costs. Moreover, the development of handy and user-friendly testing products will enable the patients to monitor their health status themselves.  


Study Objectives


This report aims to provide an in-depth analysis of the cardiopulmonary exercise testing market. The specific objectives of this cardiopulmonary exercise testing market report are given below:



  • To analyze and forecast the cardiopulmonary exercise testing systems market in terms of value and volume.

  • To provide information about the impact of covid 19 and market growth thereafter.

  • To identify the problems and prospects of cardiopulmonary exercise testing.

  • To give details about the technological viability of the product and possible further innovation areas.

  • To provide an overview of the regional market and potentially growing segments


Cardiopulmonary Exercise Testing Monitors Market Share, by Product, 2017 (%)  Cardiopulmonary Exercise Testing Market


Source: MRFR Analysis Regional Analysis


Segmentation of the Global cardiopulmonary exercise testing market, by Product



  • Cardiopulmonary Exercise Testing (CPET) Systems

  • Single-Photon Emission Computed Tomography (SPECT)

  • Echocardiogram

  • Pulse Oximeters

  • Stress Blood Pressure Monitors

  • Others


The cardiopulmonary exercise testing (CPET) system occupies the largest global market share.  This is due to their handy design, multiple uses, and affordability.  These cost-effective systems greatly simplify the work of physicians. However, pulse oximeters were in great demand recently owing to covid fear and are likely to continue the growth further.  


Segmentation of Global Cardiopulmonary Exercise Testing Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Ambulatory Surgical Centers

  • Others


Hospitals and clinics occupy the largest share of the Global cardiopulmonary exercise testing market. As hospitals are the primary place where people visit for their treatment the demand will continue rising from here. The modernization of healthcare facilities by governments in different developing countries is also likely to fuel the demand. However, Diagnostics Centres are being successful in gathering the trust of the people. Hence, this segment is showing a higher growth rate


Cardiopulmonary Exercise Testing Market Share, by Region, 2017 (%)  Cardiopulmonary Exercise Testing Market


Source: MRFR Analysis


Cardiopulmonary Exercise Testing Market Regional Analysis


Americas


North America



  • US

  • Canada

  • Mexico


South America


Europe



  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Rest of Europe


Asia-Pacific



  • China

  • India

  • Japan

  • Australia & New Zealand

  • Rest of Asia-Pacific


Rest of the world ( RoW )



  • The Middle East

  • Africa




The Americas hold the largest share in the global pulmonary exercise testing market. The prevalence of cardiovascular disorders such as a coronary artery, cardiac arrest, heart failure, angina pectoris, etc. has made people conscious about their heart health. Moreover, good healthcare infrastructure also supports the growth of the market. Rising awareness about a healthy lifestyle and the need to monitor health is going to raise the demand. 


Next to the Americas, Europe is the second-largest market. Governments' greater initiatives on health and wellness in this region are supporting the growth of the cardiopulmonary exercise testing market. Moreover, the prevalence of medical R&D Institutes is responsible for the development of innovative and user-friendly exercise testing devices and systems. Furthermore, the high disposable income of people and awareness about cardiac health are also the driving factors for the growth.


The Asia Pacific is the third-largest cardiopulmonary exercise testing market. Rising disposable incomes is bringing more people under the healthcare management system. Additionally lesser manufacturing costs of different devices and low labor costs are sustaining the growth.


The market value in the Middle East and Africa is also expected to rise during the forecast period. Economical development in these regions is expected to fuel the growth


Competitive Landscape


The global cardiopulmonary exercise testing market is dominated by many medical device manufacturers. The key global players are:- 



  • Cardinal Health

  • COSMED SRL

  • GE Healthcare

  • Hill-Rom Holdings Inc.

  • Koninklijke Philips NV

  • MGC Diagnostics Corporation

  • Nihon Kohden Corporation

  • Schiller AG

  • Masimo Corporation

  • Vyaire Medical Inc.

  • Recent Developments


In August 2019, a leading US pulmonary medical firm, Vyaire medical Inc got FDA approval for two pulmonary function testing devices. These devices named Vyntus One and Vyntus Body, are a new addition to its existing Vyntus line.


Intended Audience


This report will be beneficial for every stakeholder of the cardiopulmonary exercise testing market. It will help in decision making for those directly connected with the industry such as :


Manufacturers of Cardiopulmonary testing systems


Research Institutes


Medi care Companies


Traders of healthcare devices


Report Overview


This report provides complete details on the cardiopulmonary exercise testing market in terms of current value and future forecast. We have also identified the problems and prospects of the given market.


Moreover, technological analysis of the product will help in knowing the product better and in decision making. Furthermore, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the cardiopulmonary exercise testing market. 


 


 



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 3153.20 million
  CAGR   5.80% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cardinal Health, COSMED SRL, GE Healthcare, Halma PLC, Hill-Rom Holdings, Inc., Koninklijke Philips NV, MGC Diagnostics Corporation, NIHON KOHDEN CORPORATION, Schiller AG, Masimo Corporation, and Vyaire Medical, Inc
  Key Market Opportunities   Rising older population highly prone to degenerative diseases and chronic illnesses
  Key Market Drivers

  • Rising prevalence of cardiovascular
  • Respiratory system-related diseases
  • Advancements in technology


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation would be USD 3153.2 million by 2023.

    The Americas would ensure their domination during the forecast period.

    Low cost of labor, developing healthcare, better funding from global players, and others would trigger growth.

    The players involved are GE Healthcare, Cardinal Health, COSMED SRL, Hill-Rom Holdings, Inc., Halma PLC, MGC Diagnostics Corporation, Koninklijke Philips NV, Masimo Corporation, NIHON KOHDEN CORPORATION, Schiller AG, and Vyaire Medical, Inc.

    Company Landscape


    Company Share Analysis


    Globally there are various players operating in this market. With a well-established market in the American region, major companies have their homes in the region and generate maximum market share. These companies have expanded their operating units in various other regions as well. Moreover, there are other small and medium scale players that generate revenue from the local market.

    GLOBAL Cardiopulmonary Exercise Testing MARKET COMPANY SHARE ANALYSIS, 2017 (%)


    GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET COMPANY SHARE ANALYSIS, 2017 (%)


    Source: Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


    The above diagram displays the market share generated by the companies in the global cardiopulmonary exercise testing market in the year 2017. The major part of the market share is accounted by top three companies with 40.6% share of the global cardiopulmonary exercise testing market. The global cardiopulmonary exercise testing market is led by GE healthcare with 20.8% of the global market share followed by Koninklijke Philips N.V. with 14.4%, and Vyaire Medical Inc. being the third largest with  5.3% of the market share.


    GE Healthcare is one of the leading players in the field of cardiopulmonary exercise testing. The firm accounted for over 20.8% share in 2017. The major reason for its growth is its wide range of operating segments and wide application areas. The firm has a separate healthcare segment, which provides healthcare diagnostic imaging and clinical systems, life sciences products and services, and digital solutions to over 180 countries. Additionally, the firm has manufacturing operations in over 191 manufacturing plants located in 38 states in the US and Puerto Rico.


    Koninklijke Philips N.V. contributes to approximately 14.4% of the global cardiopulmonary exercise testing market. The firm has been largely focusing on research and development to enhance its product portfolio. For instance, the firm invested around 9.9% of sales on research and development. The firm operates in over 75 countries globally with R&D sites in the Americas, Asia, and Europe.


    Vyaire Medical Inc. accounted for the third largest spot with 9.77% of the market share. The firm has a huge geographic presence due to its 27,000 unique products for the diagnosis, treatment, and monitoring of respiratory conditions. The firm offers products through its four operating areas, namely,  respiratory diagnostics, ventilation, airway management, and operative care consumables.